DeepMed Research

Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Pembrolizumab in Treating Participants with Leukoplakia

Phase 2

Recruiting

Conditions: Leukoplakia
Erythroleukoplakia
Verrucous Oral Leukoplakia

Interventions: Biological: Pembrolizumab

First Posted Date: 2018-07-27

Last Posted Date: 2024-10-17

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT03603223

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Phase 2

Active, not recruiting

Conditions: Bladder Urothelial Carcinoma
Stage IV Bladder Cancer AJCC v8
Stage IVA Bladder Cancer AJCC v8
Stage IVB Bladder Cancer AJCC v8

Interventions: Biological: Durvalumab
Radiation: External Beam Radiation Therapy
Biological: Tremelimumab

First Posted Date: 2018-07-26

Last Posted Date: 2025-04-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT03601455

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy

Not Applicable

Withdrawn

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer

Interventions: Procedure: Image Guided Biopsy

First Posted Date: 2018-07-24

Last Posted Date: 2020-07-23

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT03596710

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase 1

Completed

Conditions: Bladder Small Cell Neuroendocrine Carcinoma
Castration-Resistant Prostate Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Prostate Carcinoma Metastatic in the Bone
Prostate Neuroendocrine Neoplasm
Prostate Small Cell Carcinoma
Stage III Bladder Cancer AJCC V8
Stage III Prostate Cancer AJCC V8
Stage III Urethral Cancer AJCC V8

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Docetaxel
Drug: Etoposide
Biological: Pembrolizumab

First Posted Date: 2018-07-11

Last Posted Date: 2023-04-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT03582475

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

Phase 3

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma

Interventions: Procedure: Computed Tomography
Other: Best Practice
Radiation: Gallium Ga 68-labeled PSMA-11
Procedure: Positron Emission Tomography

First Posted Date: 2018-07-11

Last Posted Date: 2025-05-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 193

Registration Number: NCT03582774

Locations: 🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Stage IVB Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8

Interventions: Biological: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
Biological: Pembrolizumab

First Posted Date: 2018-06-06

Last Posted Date: 2025-01-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT03546361

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

Phase 2

Active, not recruiting

Conditions: PSA Level Greater Than 0.03
PSA Progression
Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) V7
Stage II Prostate Adenocarcinoma AJCC V7
Stage III Prostate Adenocarcinoma AJCC V7

Interventions: Drug: Antiandrogen Therapy
Other: Quality-of-Life Assessment
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2018-05-31

Last Posted Date: 2023-11-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 92

Registration Number: NCT03541850

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery

Phase 2

Completed

Conditions: Recurrent Prostate Carcinoma

Interventions: Procedure: Computed Tomography
Drug: Fluciclovine F18
Drug: Gallium Ga 68-labeled PSMA-11
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2018-05-03

Last Posted Date: 2020-10-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT03515577

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Phase 1

Withdrawn

Conditions: HLA-A*0201 Positive Cells Present
NY-ESO-1 Positive Tumor Cells Present
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Radiation: 18F-FHBG
Biological: Aldesleukin
Biological: Cellular Therapy
Procedure: Computed Tomography
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Procedure: Leukapheresis
Drug: Melphalan
Drug: Plerixafor
Procedure: Positron Emission Tomography

First Posted Date: 2018-04-24

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT03506802

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Hemi-Gland Cryoablation for Prostate Cancer at UCLA

Conditions: Prostate Cancer
Prostate Adenocarcinoma
Prostate Disease

First Posted Date: 2018-04-20

Last Posted Date: 2025-05-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 100

Registration Number: NCT03503643

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy